Clinical trials initiated: Nexvax2 therapeutic vaccine for celiac disease

摘要

The biotech company ImmunsanT recently announced the initiation of clinical trials in New Zealand, Australia and the USA to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease.This inherited autoimmune disorder affects the digestive process of the small intestine. When a person with celiac disease consumes gluten, a protein found in wheat, rye and barley, the individual's immune system responds by triggering T cells to fight the offending proteins, damaging the small intestine and inhibiting the absorption of important nutrients into the body. Currently no drug therapy is available. Thus, the only option for people with celiac disease is to eliminate gluten from the diet.